Abstract
Objective
The aim of this study was to study the clinical efficacy and toxicity of combination of the radiotherapy and IP regimen for patients with local advanced esophageal cancer.
Methods
Sixty-eight cases of local advanced esophageal cancer were randomized into two groups, simple irradiation group (control group, n = 33) receiving conventional radiotherapy to a total of 60 Gy, combined group (research group, n = 35) which received the same radiotherapy as simple irradiation group plus chemotherapy with IP regimen, patients in research group were treated with infusion of Irinotecan 65 mg/m2 and DDP 30 mg/m2 on days 1 and 8. Twenty-one days was a cycle and 4 cycles were given.
Results
The remission rate, one and two year disease-free survival rate in research group were significant higher than it in control group. But the incidence of nausea, vomiting, myelosuppression and diarrhea was higher in research group.
Conclusion
The efficacy of concomitant radiotherapy and IP regimen for local advanced esophageal cancer is obviously and it can improve the survival rate of patients, which worthy of clinical application.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Jiang GL. Modern radiation therapy oncology. Shanghai: Scientific & Technical Publishers, 2003. 526–527.
Enzinger PC, Kulke MH, Clark JW, et al. A phase II trial of irinotecan in patients with previously untreated advanced esophageal and gastric adenocarcinoma. Dig Dis Sci, 2005, 50: 2218–2223.
Ajani JA, Baker J, Pisters PW, et al. Irinotecan plus cisplatin in advanced gastric or gastroesophageal junction carcinoma. Oncology, 2001, 15: 52–54.
Ilson DH, Saltz L, Enzinger P, et al. Phase II trial of weekly irinotecan P1us cisplatin in advanced esophageal cancer. J Clin Oncol, 1999, 17: 3270–3275.
Taylor S, Murthy AK, Griem KL, et al. Concomitant cisplatinl 5-FU infusion and radiotherapy in advanced head and neck cancer: 8-year analysis of results. Head Neck, 1997, 19: 684–691.
Assersohn L, Brown G, Cunningham D, et al. Phase II study of irinotecan and 5-fluorouracil/leucovorin in patients with primary refractory or relapsed advanced oesophageal and gastric carcinoma. Ann Oncol, 2004, 15: 64–69.
Fu JJ, Li Y, Li HY, et al. Effects of the combination of topoisomerase I inhibitors and celecoxib, a selective cylooxygenase-2 inhibitor on colorectal cancer. World Chin J Digestol (Chinese), 2005, 13: 1985–1991.
Burkart C, Bokemeyer C, Klump B, et al. A phase II trial of weekly irinotecan in cisplatin-refractory esophagealcancer. Anticancer Res, 2007, 27: 2845–2848.
Ilson DH, Saltz L, Enzinger P, et al. Phase II trial of weekl irinotecan p1us cisplatin in advanced esophageacancer. J Clin Oncol, 1999, 17: 3270–3275.
Ajani JA, Baker J, Pisters PW, et al. CPT-11 plus cisplatin in patients with advanced, untreated gastric or gastroesophageal junction carcinoma: results of a phase II study. Cancer, 2002, 94: 641–646.
Ilson DH. Phase II trial of weekly irinotecan/cisplatin in advanced esophageal cancer. Oncology, 2004, 18: 22–25.
Lee DH, Kim HT, Han JY, et al. A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus. Cancer Chemother Pharmacol, 2008, 61: 83–88.
Michel P, Adenis A, Di Fiore F, et al. Induction cisplatin-irinotecan followed by concurrent cisplatin-irinotecan and radiotherapy without surgery in oesophageal cancer: multicenter phase II FFCD trial. Br J Cancer, 2006, 95: 705–709.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Gao, F., Jia, L., Du, H. et al. A clinical study of combination of radiotherapy and IP regimen in the treatment of patients with local advanced esophageal cancer. Chin. -Ger. J. Clin. Oncol. 8, 506–509 (2009). https://doi.org/10.1007/s10330-009-0113-8
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10330-009-0113-8